Cargando…
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response
Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6%...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998869/ https://www.ncbi.nlm.nih.gov/pubmed/33801380 http://dx.doi.org/10.3390/vaccines9030207 |
_version_ | 1783670651683340288 |
---|---|
author | Tsitsilonis, Ourania E. Paraskevis, Dimitrios Lianidou, Evi Terpos, Evangelos Akalestos, Athanasios Pierros, Vassilios Kostaki, Evangelia Georgia Kastritis, Efstathios Moutsatsou, Paraskevi Politou, Marianna Scorilas, Andreas Sphicopoulos, Thomas Thomaidis, Nikolaos Trougakos, Ioannis P. Tsakris, Athanassios Voulgaris, Nikolaos Daskalaki, Christina C. Evangelakou, Zoi Fouki, Christina Gianniou, Despoina D. Gumeni, Sentiljana Kostopoulos, Ioannis V. Manola, Maria S. Orologas-Stavrou, Nikolaos Panteli, Chrysanthi Papanagnou, Eleni-Dimitra Rousakis, Pantelis Sklirou, Aimilia D. Smilkou, Stavroula Stergiopoulou, Dimitra Tsiodras, Sotirios Dimopoulos, Meletios-Athanasios Sfikakis, Petros P. |
author_facet | Tsitsilonis, Ourania E. Paraskevis, Dimitrios Lianidou, Evi Terpos, Evangelos Akalestos, Athanasios Pierros, Vassilios Kostaki, Evangelia Georgia Kastritis, Efstathios Moutsatsou, Paraskevi Politou, Marianna Scorilas, Andreas Sphicopoulos, Thomas Thomaidis, Nikolaos Trougakos, Ioannis P. Tsakris, Athanassios Voulgaris, Nikolaos Daskalaki, Christina C. Evangelakou, Zoi Fouki, Christina Gianniou, Despoina D. Gumeni, Sentiljana Kostopoulos, Ioannis V. Manola, Maria S. Orologas-Stavrou, Nikolaos Panteli, Chrysanthi Papanagnou, Eleni-Dimitra Rousakis, Pantelis Sklirou, Aimilia D. Smilkou, Stavroula Stergiopoulou, Dimitra Tsiodras, Sotirios Dimopoulos, Meletios-Athanasios Sfikakis, Petros P. |
author_sort | Tsitsilonis, Ourania E. |
collection | PubMed |
description | Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARS-CoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptor-binding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic. |
format | Online Article Text |
id | pubmed-7998869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79988692021-03-28 SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response Tsitsilonis, Ourania E. Paraskevis, Dimitrios Lianidou, Evi Terpos, Evangelos Akalestos, Athanasios Pierros, Vassilios Kostaki, Evangelia Georgia Kastritis, Efstathios Moutsatsou, Paraskevi Politou, Marianna Scorilas, Andreas Sphicopoulos, Thomas Thomaidis, Nikolaos Trougakos, Ioannis P. Tsakris, Athanassios Voulgaris, Nikolaos Daskalaki, Christina C. Evangelakou, Zoi Fouki, Christina Gianniou, Despoina D. Gumeni, Sentiljana Kostopoulos, Ioannis V. Manola, Maria S. Orologas-Stavrou, Nikolaos Panteli, Chrysanthi Papanagnou, Eleni-Dimitra Rousakis, Pantelis Sklirou, Aimilia D. Smilkou, Stavroula Stergiopoulou, Dimitra Tsiodras, Sotirios Dimopoulos, Meletios-Athanasios Sfikakis, Petros P. Vaccines (Basel) Article Between June and November 2020, we assessed plasma antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein in 4996 participants (aged 18–82 years, 34.5% men) from the National and Kapodistrian University of Athens. The weighted overall prevalence was 1.6% and monthly prevalence correlated with viral RNA-confirmed SARS-CoV-2 infections in Greece, in the same period. Notably, 49% of seropositive cases reported no history of SARS-CoV-2 infection-related clinical symptoms and 33% were unsuspected of their previous infection. Additionally, levels of anti-SARS-CoV-2 antibodies against the spike-protein receptor-binding domain were similar between symptomatic and asymptomatic individuals, irrespective of age and gender. Using Food and Drug Administration Emergency Use Authorization-approved assays, these results support the need for such studies on pandemic evaluation and highlight the development of robust humoral immune responses even among asymptomatic individuals. The high percentage of unsuspected/asymptomatic active cases, which may contribute to community transmission for more days than that of cases who are aware and self-isolate, underscores the necessity of measures across the population for the efficient control of the pandemic. MDPI 2021-03-02 /pmc/articles/PMC7998869/ /pubmed/33801380 http://dx.doi.org/10.3390/vaccines9030207 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Tsitsilonis, Ourania E. Paraskevis, Dimitrios Lianidou, Evi Terpos, Evangelos Akalestos, Athanasios Pierros, Vassilios Kostaki, Evangelia Georgia Kastritis, Efstathios Moutsatsou, Paraskevi Politou, Marianna Scorilas, Andreas Sphicopoulos, Thomas Thomaidis, Nikolaos Trougakos, Ioannis P. Tsakris, Athanassios Voulgaris, Nikolaos Daskalaki, Christina C. Evangelakou, Zoi Fouki, Christina Gianniou, Despoina D. Gumeni, Sentiljana Kostopoulos, Ioannis V. Manola, Maria S. Orologas-Stavrou, Nikolaos Panteli, Chrysanthi Papanagnou, Eleni-Dimitra Rousakis, Pantelis Sklirou, Aimilia D. Smilkou, Stavroula Stergiopoulou, Dimitra Tsiodras, Sotirios Dimopoulos, Meletios-Athanasios Sfikakis, Petros P. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response |
title | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response |
title_full | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response |
title_fullStr | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response |
title_full_unstemmed | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response |
title_short | SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response |
title_sort | sars-cov-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998869/ https://www.ncbi.nlm.nih.gov/pubmed/33801380 http://dx.doi.org/10.3390/vaccines9030207 |
work_keys_str_mv | AT tsitsilonisouraniae sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT paraskevisdimitrios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT lianidouevi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT terposevangelos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT akalestosathanasios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT pierrosvassilios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT kostakievangeliageorgia sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT kastritisefstathios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT moutsatsouparaskevi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT politoumarianna sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT scorilasandreas sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT sphicopoulosthomas sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT thomaidisnikolaos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT trougakosioannisp sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT tsakrisathanassios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT voulgarisnikolaos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT daskalakichristinac sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT evangelakouzoi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT foukichristina sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT giannioudespoinad sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT gumenisentiljana sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT kostopoulosioannisv sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT manolamarias sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT orologasstavrounikolaos sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT pantelichrysanthi sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT papanagnouelenidimitra sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT rousakispantelis sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT sklirouaimiliad sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT smilkoustavroula sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT stergiopouloudimitra sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT tsiodrassotirios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT dimopoulosmeletiosathanasios sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse AT sfikakispetrosp sarscov2infectionisasymptomaticinnearlyhalfofadultswithrobustantispikeproteinreceptorbindingdomainantibodyresponse |